![](https://www.i-mak.org/wp-content/uploads/2023/02/Stop-Big-Pharma-Drug-Prices.webp)
Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
After India, I-MAK files legal challenge against Gilead’s hepatitis C drug sofosbuvir in China
Building on 2015 rejection of Gilead’s patent application for hepatitis C, legal challenge to Gilead’s remaining patent in China that blocks hep C treatment for up to 13 million people
Gilead faces fresh patent challenges over hepatitis C drugs in India
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Sovaldi patent ruling not a game-changer, yet NGO, drugmaker both weigh appeals to partial ruling.
Partial Revocation Of EPO Patent On Sofosbuvir, Key For Hepatitis C
European regulator amends some Gilead hep C patent claims
I-MAK, Indian Health Advocates Appeal Patent Office Reversal on Gilead’s Hepatitis C Drug
China Declined The Patent Application Of Gilead Sciences, Inc.’s Sovaldi Prodrug
China rejects patent linked to Gilead hepatitis C drug
Partner with us now to build
a more just and equitable
medicine system for all.